Inspire Vet Partners Sells Unregistered Equity Securities

TL;DR

**Inspire Vet Partners just sold new shares privately, likely diluting existing stock.**

AI Summary

Inspire Veterinary Partners, Inc. entered into a material definitive agreement on January 2, 2024, involving the unregistered sale of equity securities. This means the company issued new shares without a public offering, likely to specific investors, which could dilute the value of existing shares. For current or potential shareholders, this matters because an increase in the total number of shares outstanding can reduce the earnings per share and voting power of their existing holdings.

Why It Matters

The unregistered sale of equity securities can dilute existing shareholder value by increasing the total number of shares outstanding without a public offering.

Risk Assessment

Risk Level: medium — The unregistered sale of equity securities can lead to dilution for existing shareholders, impacting their ownership percentage and potentially the stock price.

Analyst Insight

A smart investor would investigate the terms of the material definitive agreement and the specifics of the unregistered equity sales to understand the extent of potential dilution and its impact on future earnings per share before making any investment decisions.

Key Players & Entities

• Inspire Veterinary Partners, Inc. (company) — the registrant filing the 8-K
• January 2, 2024 (date) — date of the earliest event reported regarding the material definitive agreement and unregistered sales of equity securities
• Nevada (company) — state of incorporation for Inspire Veterinary Partners, Inc.
• $0.0001 (dollar_amount) — par value of Class A Common Stock
• IVP (company) — trading symbol for Inspire Veterinary Partners, Inc.'s Class A Common Stock

Forward-Looking Statements

• The stock price of IVP may experience downward pressure due to potential dilution from the unregistered sale of equity securities. (IVP) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 IVP Nasdaq Capital Market Indicat
• $200,000 — A preferred stock for gross proceeds of $200,000. The issuance and sale of the Series A

Filing Documents

• ea191324-8k_inspire.htm (8-K) — 29KB
• 0001213900-24-001967.txt ( ) — 198KB
• ivp-20240102.xsd (EX-101.SCH) — 3KB
• ivp-20240102_lab.xml (EX-101.LAB) — 33KB
• ivp-20240102_pre.xml (EX-101.PRE) — 22KB
• ea191324-8k_inspire_htm.xml (XML) — 3KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. On January 2, 2024, Inspire Veterinary Partners, Inc. ("Inspire" or the "Company") entered into a subscription agreement (the "Subscription Agreement") with Target Capital 1, LLC ("Target"), pursuant to which Target purchased 20,000 shares of Series A preferred stock for gross proceeds of $200,000. The issuance and sale of the Series A preferred stock to Target was consummated in a privately negotiated transaction exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. The foregoing description of the Subscription Agreement in this Item 1.01 of this Current Report on Form 8-K is qualified in its entirety by reference to the full text of the Subscription Agreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated herein by reference.

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.02. The Company expects to use the proceeds of the sale of the Series A preferred stock for general working capital purposes.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements regarding the Company's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions related to the sale and issuance of shares of Series A preferred stock pursuant to the Subscription Agreement. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in the Company's Registration Statement on Form S-1 related to the Company's initial public offering (File No. 333-271198), and in the Company's other filings with the Commission. Forward-looking statements contained in this Current Report on Form 8-K are made as of the date hereof, and the Company undertakes no duty to update such information, except as required under applicable law. Item. 9.01. Financial Statements and Exhibits Exhibit No. Description 10.1 Subscription Agreement, dated January 2, 2024, between Inspire Veterinary Partners, Inc. and Target Capital 1 LLC* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Incorporated by reference to Registration Statement on Form S-1 filed January 4, 2024. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 INSPIRE VETERINARY PARTNERS, INC. By: /s/ Kimball Carr Name: Kimball Carr Title: Chair, President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR